Alzheimer’s - G2 Intelligence

Expert Q&A: Full Approval for Alzheimer’s Blood Tests Not Far Off

Andreas Jeromin, PhD, chief scientific officer at ALZPath, discusses the current landscape of blood-based AD tests and their future.

This content is for Paid Members only.
Register

Already a member? Log in here

Alison Green, PhD, head of laboratory sciences at Scottish Brain Sciences, discusses recent developments in AD blood tests

This content is for Paid Members only.
Register

Already a member? Log in here

The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan

This content is for Paid Members only.
Register

Already a member? Log in here

G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.

This content is for Paid Members only.
Register

Already a member? Log in here